Nitroglycerin (NTG) is widely used by emergency medical services (EMS) for treatment of cardiac chest pain. Concern for precipitating hypotension in patients with inferior ST elevation myocardial infarction (STEMI) involving the right ventricle and in those with non-cardiac conditions has led some EMS systems to discontinue its use. The objectives of this study were to quantify the risk of hypotension and the benefits of pain relief in patients treated with out-of-hospital NTG for suspected STEMI. Consecutive adult patients with suspected STEMI transported by EMS to one of three participating PCI-capable hospitals were prospectively identified and maintained in a log during an 18-month study period. Investigators reviewed out-of-hospital and hospital records for initial field and emergency department (ED) vital signs, field NTG treatment, and hospital management and outcomes. A second investigator independently confirmed key data and inter-rater reliability, using the kappa statistic, was assessed on a random 10% sample of records. Patients with contraindications to NTG were excluded, including hypotension on EMS arrival and phosphodiesterase 5 inhibitor use within 48 hours. The frequency of ED hypotension, defined as a triage systolic blood pressure (SBP) less than 100mmHg, and the change in pain score were calculated in patients who received field NTG and compared to those who did not. The minimum clinically important difference (MCID) in pain score was set a priori at 1.39. Planned subgroup analyses were patients with final diagnosis of STEMI and percutaneous coronary intervention (PCI) of a mid or proximal right coronary artery (RCA) lesion. The frequency of hypotension was compared with the Cochran-Mantel-Haenszel test and change in SBP and pain score with Hodges-Lehmann’s median difference. Of 940 EMS transports for suspected STEMI, 160 were excluded for initial hypotension; thus 780 comprised the study cohort. Median age was 67 with 61% male. NTG was given to 340 (44%) patients, of whom 32 (9%) had ED hypotension compared with 54 (12%) who did not receive NTG, with a relative risk (RR) of 0.97 (95% CI 0.92, 1.02). Inter-rater reliability was excellent, kappa 0.93 (95% CI 0.80, 1.0). The average decrease in SBP was 17.4±90 mmHg and 6.9±29 mmHg in patients treated with and without NTG respectively, median difference -6 mmHg (95% CI -3, -9). The average change in pain scores for patients treated with and without NTG was -2.2±3.4 and 0±2.0 respectively, median difference -1.5 (95% CI -1.0, -2.0). Of 193 patients with confirmed STEMI, 155 (80%) received NTG. In this subgroup, ED hypotension occurred in 14 (9%) treated with NTG compared to 4 (11%) without NTG and the average pain score was -2.0±3.7 with NTG versus no change without. Finally, among patients with mid or proximal RCA lesions, 60 (80%) received NTG; there was no difference in hypotension with or without field NTG, 4/60 (7%) and 1/15 (7%) respectively. Compared to patients treated with PCI in any other location, the frequency of hypotension after NTG among patients with RCA lesions was similar, RR 0.95 (95% CI 0.87, 1.06). In this cohort of suspected or confirmed STEMI patients, field NTG resulted in pain reduction and was not associated with an increased frequency of ED hypotension, even among those with mid or proximal RCA lesions.
Read full abstract